Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial
Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022